In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - PBMTC-ONC1401
Protocol Summary
- Protocol No
- PBMTC-ONC1401
- Principal Investigator
- Julie-An Talano
- Phase
- II
- Title
- The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
- Associated Disease(s)
-
Early Phase Trials (Phase I and II)
- Description (Summary)
- There are two main purposes or parts of this study. The first part is to study the biology of blood cells from transplant patients and blood cells from the donors. Patients may be on the first part of the study without being on the second part. The second part of this study is looking at donors with special cancer-fighting cells with unique proteins on their surface called Killer Immunoglobulin-like Receptors, or KIRs. In this part of the study we are looking to see if patients receiving transplants from half-matched (haploidentical) related donors that have certain KIR types will have better results than those patients transplanted using other KIR types.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD